GANX - CIK 0001819411
Gain Therapeutics, Inc. trades as GANX. This page tracks Gain Therapeutics, Inc. through 224 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -12387.7% to -40354.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-26 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| Annual report to shareholders | ARS | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
| Insider trade | 4 | 2026-03-26 |
| Insider trade | 4 | 2026-03-26 |
The largest companies sharing Gain Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Gain Therapeutics, Inc. reported a net loss of $20.16M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.